NeuroSense provided update on clinical, operational developments in Q2

NeuroSense Therapeutics provided an update from its CEO, Alon Ben-Noon, on the Company’s clinical and operational developments during the second quarter of 2023. Phase 2b Amyotrophic Lateral Sclerosis PARADIGM Trial Completed Patient Enrollment: Topline results expected Q4 2023; 96% of participants who completed the trial chose to continue in the study and be treated with PrimeC through a 12-month open-label extension. Strategic Scientific Agreement with Biogen: Biogen will evaluate the impact of PrimeC on neurofilament levels in the plasma of participants in NeuroSense’s Phase 2b ALS PARADIGM trial; Biogen will fund this meaningful neurofilament biomarker study and upon receipt of results, has the right of first refusal to co-develop / commercialize PrimeC for the treatment of ALS for a limited time following the results. Phase 2 Alzheimer’s Disease Trial Under Preparation: Biomarker study revealed elevated levels of novel biomarker TDP-43 in AD as compared to healthy controls; Results demonstrate therapeutic potential of NeuroSense’s combination drug platform for AD; Phase 2 double-blind proof-of-concept clinical study is now under preparation, with regulatory submissions and site readiness ongoing during Q2 2023 and first patient enrolled expected in Q3 2023. Parkinson’s Disease Biomarker Study Completed : NeuroSense observed a statistically significant decrease in levels of AGO2, a novel PD biomarker, in newly diagnosed PD patient when compared to the healthy control group; Planning to co-develop PD indication with collaborators that have a core focus on Parkinson’s.